Binds Specifically-identified Amino Acid Sequence Patents (Class 530/387.9)
-
Publication number: 20140343249Abstract: A cell-killing peptide, more specifically a cell-killing CKP fusion peptide (CTD7:CKP) is disclosed, wherein a cell-killing peptide (CKP) comprising 10 amino acids in MTD of Noxa protein causing cell death, and 7 amino acids targeting a cancer cell are fused. The cell-killing CKP fusion peptide induces strong cell necrosis at various cancer cell lines (HeLa, HCT116, MCF-7, A549, BJAB, CT26, PC3 and the like) and shows strong tumor regression effect at a mouse tumor model using experimental animals, but does not show apoptosis at normal cells. Therefore, it can be broadly used to human body for treating various diseases requiring cell death, particularly, as an anti-cancer drug.Type: ApplicationFiled: December 15, 2011Publication date: November 20, 2014Applicant: INDUSTRY-ACADEMIC COOPERATION FOUNDATION, CHOSUN UNIVERSITYInventors: Tae-Hyoung Kim, Ae Ran Moon, Ji Young Kim
-
Publication number: 20140341913Abstract: The invention provides methods and compositions for treating asthma, e.g., mild or moderate asthma, in a subject using an anti-IL-13 antibody, or antigen-binding portion thereof.Type: ApplicationFiled: July 2, 2012Publication date: November 20, 2014Applicant: ABBVIE INC.Inventor: Catherine Tripp
-
Publication number: 20140341918Abstract: The invention provides compositions and methods for preventing or reducing the severity of malaria.Type: ApplicationFiled: November 30, 2012Publication date: November 20, 2014Inventors: Jonathan Kurtis, Christian Parcher Nixon, Dipak Kumar Raj, Jennifer Frances Friedman, Michal Fried, Patrick Emmet Duffy
-
Publication number: 20140341915Abstract: The present invention is concerned with diagnostic methods and means. Specifically, it relates to an antibody which specifically binds to a portion of the extracellular domain of the B7-H6 polypeptide. Moreover, said antibody is provided for use in the treatment or diagnosis of cancer or inflammatory disease. Furthermore, provided are a method for diagnosing cancer in a sample of a subject suspected to suffer from cancer or an inflammatory disease. Further, the present invention concerns a device and a kit for diagnosing cancer or an inflammatory.Type: ApplicationFiled: September 10, 2012Publication date: November 20, 2014Inventors: Adelheid Cerwenka, Gerhard Moldenhauer
-
Patent number: 8889833Abstract: The invention provides human secreted proteins (SECP) and polynucleotides which identify and encode SECP. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for diagnosing, treating, or preventing disorders associated with aberrant expression of SECP.Type: GrantFiled: October 8, 2013Date of Patent: November 18, 2014Assignee: Incyte CorporationInventors: Henry Yue, Monique G. Yao, Ameena R. Gandhi, Mariah R. Baughn, Anita Swarnakar, Narinder Walia, Madhusudan M. Sanjanwala, Michael Thorton, Vicki S. Elliott Kaulback, Yan Lu, Kimberly J. Gietzen, Neil Burford, Li Ding, April J. A. Hafalia, Y. Tom Tang, Olga Bandman, Bridget A. Warren, Cynthia D. Honchell, Dyung Aina M. Lu, Kavitha Thangaveln, Sally Lee, Yuming Xu, Junming Yang, Preeti G. Lal, Bao M. Tran, Craig H. Ison, Brendan M. Duggan, Stephanie Kareht
-
Publication number: 20140335093Abstract: The invention relates to PD-1 antibodies and PD-L1 antibodies and uses thereof.Type: ApplicationFiled: May 20, 2014Publication date: November 13, 2014Applicants: Universite de la Mediterranee, INSERM (Institut National de la Sante et de la Recherche Medicale)Inventor: Daniel Olive
-
Publication number: 20140336360Abstract: The invention discloses 155 novel phosphorylation sites identified in carcinoma and leukemia, peptides (including AQUA peptides) comprising a phosphorylation site of the invention, antibodies specifically bind to a novel phosphorylation site of the invention, and diagnostic and therapeutic uses of the above.Type: ApplicationFiled: December 31, 2013Publication date: November 13, 2014Inventors: Peter Hornbeck, Judit Villen, Albrecht Moritz, John Rush, Steven Gygi, Sean Beausoleil, Scott Gerber
-
Publication number: 20140335094Abstract: Purified genes encoding cytokine from a mammal, reagents related thereto including purified proteins, specific antibodies, and nucleic acids encoding this molecule are provided. Methods of using said reagents and diagnostic kits are also provided.Type: ApplicationFiled: July 14, 2014Publication date: November 13, 2014Inventors: Birgit Oppmann, Rene de Waal Malefyt, Donna M. Rennick, Robert A. Kastelein, Maria T. Wiekowski, Sergio A. Lira, Satwant K. Narula
-
Publication number: 20140335121Abstract: The present invention has as its object to provide a process for determining the degree of pathogenicity of infecting bacterial strains in the case of canine periodontal disease. The present inventors found that Porphyromonas gulae is a major pathogen of canine periodontal disease, and demonstrated that the fimA genes encoding FimA (fimbrillin) protein which constitute fimbriae of this bacterium are classified into three major groups, and that each of the groups is correlated with the pathogenicity of this bacterium as a pathogenic bacterial of periodontal disease. Thus the inventors completed the present invention.Type: ApplicationFiled: December 13, 2012Publication date: November 13, 2014Inventors: Fumitoshi Asai, Yukio Kato, Mitsuyuki Shirai, Masaru Murakami, Kazuhiko Nakano, Ryota Nomura
-
Publication number: 20140335092Abstract: The present invention provides vaccine compositions comprising OmpA, or antigenic fragments thereof, and related methods of active immunization against A. baumannii infection. The invention also provides antibodies and antigen-binding parts thereof that specifically bind to OmpA, and related methods of passive immunization against A. baumannii infection. The compositions and methods of the invention are useful for preventing or treating A. baumannii infections, including those caused by strains resistant to carbapenems and all other antibiotics except colistin or tigecycline, also referred to as extreme drug resistant (XDR) A. baumannii infections, and those resistant to every FDA approved antibiotic, also referred to as pan-drug resistant (PDR) A. baumannii infections.Type: ApplicationFiled: May 15, 2014Publication date: November 13, 2014Applicant: Los Angeles Biomedical Research Institute at Harbor-UCLA Medical CenterInventors: Brad J. SPELLBERG, Lin LIN, Ashraf IBRAHIM, Guanpingsheng LUO
-
Publication number: 20140335090Abstract: Disclosed are a novel therapeutic agent for cancer such as esophageal squamous cell carcinoma, a method for predicting the prognosis of cancer, and a method for detecting, or predicting the prognosis of, cancer such as esophageal squamous cell carcinoma using a sample that can be collected less invasively. The therapeutic agent for cancer comprises as an effective component an antibody that undergoes antigen-antibody reaction with FGFRL1 to suppress the growth of cancer cells, or an antigen-binding fragment thereof. The method for predicting the prognosis of cancer comprises investigating the expression level of FGFRL1 in a cancer tissue separated from a living body, and, in this method, a high expression level of FGFRL1 indicates poor prognosis.Type: ApplicationFiled: March 30, 2012Publication date: November 13, 2014Applicant: KYOTO UNIVERSITYInventors: Soken Tsuchiya, Gozoh Tsujimoto, Kazuharu Shimizu, Yutaka Shimada, Kazuhiro Tsukada
-
Publication number: 20140335504Abstract: The present invention provides, among other things, technologies and methodologies for detection, treatment, and/or prevention of influenza transmission and/or infection. The present invention also provides technologies for monitoring influenza HA variants with particular degrees of susceptibility to mutation for human adaptation.Type: ApplicationFiled: February 7, 2014Publication date: November 13, 2014Applicant: Massachusetts Institute of TechnologyInventors: Ram Sasisekharan, Rahul Raman, Kannan Tharakaraman, Karthik Viswanathan, Nathan Wilson Stebbins
-
Publication number: 20140336364Abstract: A protein which induces the IFN-? production by immunocompetent cells and has a molecular weight of 19,000±5,000 daltons on SDS-PAGE or gel filtration method and a pI of 4.8±1.0 on chromatofocusing. The protein is isolated from mouse liver and can be purified by a monoclonal antibody specific to it. The monoclonal antibody can be also used for assaying the protein.Type: ApplicationFiled: July 31, 2014Publication date: November 13, 2014Inventors: Haruki OKAMURA, Tadao TANIMOTO, Kakuji TORIGOE, Toshi KUNIKATA, Mutsuko TANIGUCHI, Keizo KOHNO, Masashi KURIMOTO
-
Publication number: 20140335119Abstract: The present invention relates to the field of the in vitro diagnosis of the progression status of an infection of an individual with a virus belonging to the family of the Human Immunodeficiency Viruses (HIV) as well as with the therapeutical treatment of this infectious disease. The invention also relates to immunological compounds and vaccine compositions comprising a polypeptide derived from gp41.Type: ApplicationFiled: May 23, 2014Publication date: November 13, 2014Applicants: Institut National de la Sante et de la Recherche Medicale (INSERM), Assistance Publique Hopitaux de ParisInventors: Vincent VIEILLARD, Patrice DEBRE
-
Publication number: 20140336236Abstract: Novel ALK and NTRK1 fusion molecules and uses are disclosed.Type: ApplicationFiled: April 21, 2014Publication date: November 13, 2014Applicant: FOUNDATION MEDICINE, INC.Inventors: Maureen T. Cronin, Doron Lipson, Roman Yelensky
-
Publication number: 20140335096Abstract: Provided are monoclonal antibodies, or antigen-binding fragments thereof, that bind to glucagon. These antibodies are useful in immunoassays of glucagon levels, and/or in vivo, ex vivo or in vitro immunochemical and other imaging methods for detecting glucagon levels, and for diagnostic, prognostic and predictive purposes, and for optimizing therapeutic regimens in patients in which glucagon signaling is implicated in pathogenesis.Type: ApplicationFiled: November 27, 2012Publication date: November 13, 2014Inventors: David Edward Watson, Robert W. Siegel, Nan Jia, John Harrison Sloan
-
Publication number: 20140335091Abstract: The present invention provides antagonizing antibodies that bind to glucagon receptor and methods of using same. The anti-glucagon receptor antibodies can be used therapeutically to lower glucose levels in blood, and can be in the prevention and/or treatment of glucose-related disorders, including diabetes, hyperglycemia, hyperinsulinemia, impaired fasting glucose, impaired glucose tolerance, dyslipidemia, or metabolic syndrome.Type: ApplicationFiled: May 2, 2014Publication date: November 13, 2014Applicant: RINAT NEUROSCIENCE CORP.Inventors: Alison Jane FORGIE, Javier Fernando CHAPARRO RIGGERS, Edward Roland LAVALLIE, Chia-Yang LIN, Lidia MOSYAK, Andrea ROSSI, Thomas John VAN BLARCOM
-
Publication number: 20140335628Abstract: Method of obtaining and/or verifying a binder to prepro-Vasopressin (SEQ ID NO. 1) or fragments thereof of at least 6 amino acids in length, including Copeptin (SEQ ID NO. 2), comprising at least one of the steps of: a) generating the binder using a developer comprising an amino acid sequence of at least 6 amino acids in length contained in an amino acid sequence corresponding to the C-terminal part but lacking amino acid 164 of prepro-Vasopressin (SEQ ID NO. 1); b) determining whether the binder is capable of binding to an amino acid sequence of at least 4 amino acids in length contained in an amino acid sequence corresponding to the C-terminal part but lacking amino acid 164 of prepro-Vasopressin (SEQ ID NO. 1); c) selecting and optionally isolating the binder from a plurality of binders which is capable of binding to an amino acid sequence contained in an amino acid sequence corresponding to the C-terminal part but lacking amino acid 164 of prepro-Vasopressin (SEQ ID NO.Type: ApplicationFiled: June 26, 2012Publication date: November 13, 2014Applicant: B.R.A.H.M.S. GMBHInventor: Joachim Struck
-
Patent number: 8883145Abstract: Methods for treating cancer comprising administering a DLL4 antagonist and one or more anti-hypertensive agents are described. Also described are pharmaceutical compositions comprising a DLL4 antagonist and one or more anti-hypertensive agents, and kits comprising the same.Type: GrantFiled: October 18, 2010Date of Patent: November 11, 2014Assignee: Oncomed Pharmaceuticals, Inc.Inventors: Robert Joseph Stagg, Steven Eugene Benner
-
Publication number: 20140329911Abstract: Provided herein are methods for predicting efficacy of a DNA (cytosine-5)-methyltransferase 1 (DNMT1) inhibitor treatment in a subject having a cancer, methods of identifying a subject having a cancer that is more likely to respond to a DNMT1 inhibitor treatment, and methods of selecting a treatment for a subject having a cancer that include determining a level of SOX9 in a sample containing cells from a subject having a cancer. Also provided are methods of treating a subject having a cancer that include selectively administering a DNMT1 inhibitor to a subject having cancer determined to have an elevated level of SOX9 in a sample containing cells from the subject compared to a reference level. Also provided are antibodies and antigen-binding antibody fragments that specifically bind to SOX9, and nucleic acid sequences that contain at least 10 nucleotides complementary to a contiguous sequence present in a SOX9 nucleic acid for use in these methods.Type: ApplicationFiled: March 7, 2012Publication date: November 6, 2014Applicant: University of Louisville Research Foundation, Inc.Inventors: Paula J. Bates, Mohammad Tariq Malik, Francesca R. Salipur
-
Publication number: 20140328850Abstract: This disclosure relates to apelin antigen-binding proteins and methods of using the apelin antigen-binding proteins. The antigen-binding protein may comprise an antibody to apelin and can be used to treat pathological conditions involving angiogenesis. The pathological conditions can comprise cancer or retinopathy and/or retinopathy-related complications.Type: ApplicationFiled: July 17, 2012Publication date: November 6, 2014Inventors: Shu-Chen Lu, Minghan Wang
-
Publication number: 20140328831Abstract: The present invention relates generally to tissue differentiation factor (TDF) analogs. More specifically, the invention relates to structure-based methods and compositions useful in designing, identifying, and producing molecules which act as functional modulators of TDF-like receptors. The invention further relates to methods of detecting, preventing, and treating TDF-associated disorders.Type: ApplicationFiled: March 24, 2014Publication date: November 6, 2014Inventors: William D. Carlson, Peter C. Keck
-
Publication number: 20140329312Abstract: The present invention a method for producing a human immunoglobulin G (IgG) antibody using a prime-boost regime in a Bone Marrow Liver Thymic (BLT) mouse.Type: ApplicationFiled: November 26, 2012Publication date: November 6, 2014Inventors: William G. North, Steven N. Fiering
-
Publication number: 20140328846Abstract: A method of inhibiting alternative complement pathway activation in a mammal includes administering an amount of an antibody and/or fragment thereof that specifically binds to an epitope of the N terminus end of properdin effective to the inhibit alternative complement pathway in the subject.Type: ApplicationFiled: June 11, 2014Publication date: November 6, 2014Inventor: Rekha Bansal
-
Publication number: 20140328754Abstract: A radioactive metal-labeled anti-cadherin antibody which is obtained by binding a radioactive metallic element to an anti-cadherin antibody via a metal-chelating reagent.Type: ApplicationFiled: June 18, 2014Publication date: November 6, 2014Applicants: Fujifilm RI Pharma Co., LTD, Perseus Proteomics Inc.Inventors: Akihiro HINO, Akio Nagano, Masahiko Watanabe, Tadasi Matsuura, Hirokazu Satoh, Fumiko Nomura, Katsuyuki Mitomo
-
Publication number: 20140329995Abstract: The invention discloses a polypeptide capable of binding immunoglobulins or immunoglobulin-containing proteins, which polypeptide comprises six or more domains of protein Z or the C domain of protein A or a functional variant thereof. It also discloses separation matrices comprising the polypeptide and methods of using the separation matrices for separation of immunoglobulins or immunoglobulin-containing proteins.Type: ApplicationFiled: November 28, 2012Publication date: November 6, 2014Applicant: GE HEALTHCARE BIO-SCIENCES ABInventors: Hans J. Johansson, Ronnie Palmgren
-
Publication number: 20140328853Abstract: Subject matter of the present invention is an anti-adrenomedullin (ADM) antibody or an anti-adrenomedullin antibody fragment or an anti-ADM non-Ig scaffold for use in therapy of a chronical or acute disease or acute condition of a patient for prevention or reduction of organ dysfunction or organ failure. In a preferred embodiment subject matter of the invention is an anti-ADM antibody or an anti-adrenomedullin antibody fragment or anti-ADM non-Ig scaffold for use in therapy of a chronical or acute disease or acute condition of a patient for prevention or reduction of kidney dysfunction or kidney failure or liver dysfunction or liver failure.Type: ApplicationFiled: November 16, 2012Publication date: November 6, 2014Applicant: ADRENOMED AGInventor: Andreas Bergmann
-
Publication number: 20140328852Abstract: The invention relates to an immunogenic peptide of eight amino acids that is generated naturally in the intestine of celiac patients by means of the hydrolysis of ingested gluten. In addition, the invention relates to the use of the peptide, or antibodies generated against same, for the in vitro monitoring and/or diagnosis of celiac disease, as well as to the use of such antibodies for the detection of gluten in food. The invention further relates to the use of the aforementioned peptide as a therapeutic target for the development of compounds or compositions for use in the diagnosis, treatment and/or prevention of this pathological condition, as well as to the use of the peptide and the antibodies against same for the prevention and/or treatment of celiac disease.Type: ApplicationFiled: September 28, 2012Publication date: November 6, 2014Inventors: David Bernardo Ordiz, Jose Antonio Garrote Adrados, Alfredo Ramon Blanco Quiros, Eduardo Arranz Sanz, Angel Cebolla Ramirez
-
Publication number: 20140328851Abstract: Herein are described two antibodies that can inhibit CETP-lipoproteins interaction and CETP activity. Presently described are an antibody or fragment thereof capable of specifically binding to an epitope of the N-terminal or C-terminal domains of CETP and methods of using these antibodies for separation, identification, diagnosis and therapy.Type: ApplicationFiled: May 15, 2014Publication date: November 6, 2014Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIAInventors: Gang Ren, Lei Zhang
-
Publication number: 20140328849Abstract: The invention provides anti-CRTh2 antibodies and methods of using the same.Type: ApplicationFiled: March 14, 2014Publication date: November 6, 2014Applicant: GENENTECH, INC.Inventors: Karin REIF, Isidro HOTZEL, Jo-Anne S. HONGO, Tao HUANG, Yonglei SHANG, Meredith HAZEN
-
Patent number: 8877189Abstract: Binding members, especially antibody molecules, for interleukin (IL)-4 receptor alpha (IL-4R?), and their therapeutic use e.g. in treating or preventing disorders associated with IL-4R?, IL-4 and/or IL-13, examples of which are asthma and COPD.Type: GrantFiled: June 6, 2013Date of Patent: November 4, 2014Assignee: MedImmune LimitedInventors: Per-Olof Fredrik Eriksson, Karin Von Wachenfeldt, Suzanne Cohen, Claire Louise Dobson, Deborah Louise Lane
-
Patent number: 8877449Abstract: The present invention provides markers that can selectively distinguish pancreatic progenitor cells. The present invention also provides methods for distinguishing pancreatic progenitor cells by using the markers as an indicator, and reagents to be used in the methods. The present inventors successfully identified the surface marker Nephrin-like 3 (Neph3) which is specifically expressed in pancreatic progenitor cells, and isolated pancreatic progenitor cells using the marker as an indicator or such. Viable pancreatic progenitor cells can be selected by using Neph3 as an indicator without using translated products and transcripts of any foreign genes. The marker is useful in preparing and identifying pancreatic progenitor cells which are applied to regenerative medicine or such for treatment of pancreatic diseases.Type: GrantFiled: December 18, 2009Date of Patent: November 4, 2014Assignee: Eisai R&D Management Co., Ltd.Inventors: Yuichi Ono, Tomoya Nakatani, Yasuko Nakagawa
-
Publication number: 20140322223Abstract: The invention provides compositions and methods for detecting and/or modulating TOX3 gene expression and/or biological activity. Such compositions and methods find utility in the detection and/or treatment of certain subsets of cancers, e.g. breast cancer. In particular, the inventive compositions and methods are drawn to production and use of anti-TOX3 antibodies and TOX3 nucleic acids for both detection and modulation of TOX3. The invention also provides for pharmaceutical compositions and methods for the modulation of TOX3 in a subject in need thereof. Further aspects of the invention relate to transgenic mice that either overexpress or inducibly express TOX3.Type: ApplicationFiled: May 21, 2014Publication date: October 30, 2014Applicant: CEDARS-SINAI MEDICAL CENTERInventor: Jonathan Kaye
-
Publication number: 20140322220Abstract: The present invention provides antibodies, or antigen-binding antibody fragments thereof, or variants thereof which reduce the cell surface expression of FGFR2 after binding to FGFR2 in both cells overexpressing FGFR2 and cells expressing mutated FGFR2. Also provided are antibody-based therapies for FGFR2-related diseases or conditions such as cancer. Antibodies of the invention also can be used in the diagnostics field. The invention also provides nucleic acid sequences encoding the foregoing antibodies, vectors containing the same, pharmaceutical compositions and kits with instructions for use.Type: ApplicationFiled: November 22, 2012Publication date: October 30, 2014Applicant: BAYER INTELLECTUAL PROPERTY GMBHInventors: Axel Harrenga, Charlotte Christine Kopitz, Stefanie Hammer, Frank Dittmer, Sven Golfier, Mark Trautwein, Sandra Bruder, Juergen Franz, Beatrix Stelte-Ludwig, Lars Linden, Ricarda Finnern, Simone Greven, Jan Tebbe
-
Publication number: 20140322306Abstract: The invention provides a molecule that inhibits or prevents an interaction between a Src family kinase and an androgen or estradiol receptor, for use in preventing or treating a non-cancerous condition in which an activity of AR and/or ER is a contributory factor in a subject, or for use in preventing or treating a cancerous condition in which an activity of AR and/or ER is a contributory factor in a subject who wishes to preserve fertility, or for use in preventing or treating a gynaecological condition in which an activity of AR and/or ER is a contributory factor in a subject.Type: ApplicationFiled: November 1, 2012Publication date: October 30, 2014Inventors: Mark Eccleston, Satu Vainikka, George Steven Morris
-
Publication number: 20140322244Abstract: The technology described herein relates to antibodies and/or polypeptides which bind to MIC and inhibit MIC shedding. Methods of using such antibodies and/or polypeptides for the treatment of cancer are also described herein.Type: ApplicationFiled: May 1, 2014Publication date: October 30, 2014Applicant: UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATIONInventor: Jennifer D. Wu
-
Publication number: 20140322130Abstract: The present invention relates to specific binding members, particularly antibodies and fragments thereof, which bind to EGFR on tumor cells that overexpress EGFR, and on tumor cells that express the truncated version of the EGFR receptor, de2-7 EGF. In particular, the epitope recognized by the specific binding members, particularly antibodies and fragments thereof, is enhanced or evident upon aberrant post-translational modification. These specific binding members are useful in the diagnosis and treatment of cancer. The binding members of the present invention may also be used in therapy in combination with chemotherapeutics or anti-cancer agents and/or with other antibodies or fragments thereof.Type: ApplicationFiled: March 26, 2014Publication date: October 30, 2014Applicant: LUDWIG INSTITUTE FOR CANCER RESEARCH LTD.Inventors: Andrew M. Scott, Terrance Grant Johns, George Mark, Anne Murray, Christoph Renner, Gerd Ritter
-
Publication number: 20140322161Abstract: The present invention relates to a pharmaceutical composition comprising, by way of active ingredient, at least one polypeptide comprising, or constituted by a sequence constituted by at least 8 contiguous amino acids and from at the most 30 contiguous amino acids chosen from within the interleukin-6 sequence and from at the most 30 contiguous amino acids chosen from within the complete IL-6 sequence.Type: ApplicationFiled: August 9, 2012Publication date: October 30, 2014Applicant: PEPTINOV SASInventors: Lucille Desallais, Mattieu Montes, Jean-Francois Zagury
-
Publication number: 20140322224Abstract: The invention relates to monoclonal antibodies (mAbs) that bind to serotransferrin (TF), hybridoma lines that secrete these antibodies or fragments thereof, and the use of these antibodies to detect TF antigens. Methods and uses for detecting prostate cancer, as well as methods and uses for distinguishing early and late stage prostate cancer are encompassed.Type: ApplicationFiled: November 9, 2012Publication date: October 30, 2014Applicant: ALPER BIOTECH LLCInventor: Ozge Alper
-
Publication number: 20140322129Abstract: The invention provides anti-B7-H4 antibodies and immunoconjugates and methods of using the same.Type: ApplicationFiled: March 13, 2014Publication date: October 30, 2014Applicant: Genentech, Inc.Inventors: Steven R. Leong, Andrew Polson, Paul Polakis, Yan Wu, Wei-Ching Liang, Ron Firestein
-
Patent number: 8871206Abstract: Human anti-human folate receptor beta (FR?) antibodies and antigen-binding fragments thereof are described, as well as methods of using such antibodies and fragments to treat inflammatory disorders or cancers expressing cell surface FR?.Type: GrantFiled: March 8, 2013Date of Patent: October 28, 2014Assignees: Purdue Research Foundation, The United States of America, as Represented by the Secretary Department of Health and Human ServicesInventors: Philip S. Low, Dimiter S. Dimitrov, Yang Feng, Jiayin Shen
-
Publication number: 20140314768Abstract: Methods and compositions for diagnosing and treating diseases, particularly cancer, associated with differential expression of cancer-associated targets (CAT) in disease cells compared to healthy cells are provided. Also provided are antagonists and agonists of CAT, and methods for screening agents that modulate CAT level or activity in vivo or in vitro.Type: ApplicationFiled: December 6, 2013Publication date: October 23, 2014Applicant: CELERA CORPORATIONInventors: Steve RUBEN, Karen VAN ORDEN, Bruno DOMON, Candy LEE, Tao HE, Mehdi MESRI, Elizabeth JOSELOFF, Katherine MCKINNON, Paul MOORE, Charles BIRSE
-
Publication number: 20140316186Abstract: The present invention is directed towards isolated antibodies that bind to GRP78 and TIP-1.Type: ApplicationFiled: January 28, 2014Publication date: October 23, 2014Inventors: Dennis E. Hallahan, Heping Yan
-
Publication number: 20140314770Abstract: The present invention provides a method for diagnosing and detecting diseases associated with kidney. The present invention provides one or more proteins or fragments thereof, peptides or nucleic acid molecules differentially expressed in kidney diseases (KCAT) and antibodies binds to KCATs. The present invention provides that KCATs are used as targets for screening agents that modulates the KCAT activities. Further the present invention provides methods for treating diseases associated with kidney.Type: ApplicationFiled: February 5, 2014Publication date: October 23, 2014Applicant: Celera CorporationInventors: Elizabeth JOSELOFF, Steve RUBEN, Tao HE
-
Publication number: 20140314774Abstract: Provided herein are antibodies specific for HER3. Also provided are methods of treating cancer in a subject comprising administering an effective amount of the antibodies described herein to the subject.Type: ApplicationFiled: November 9, 2012Publication date: October 23, 2014Inventors: Tong Zhou, Donald J. Buchsbaum, Enyun Shen, Xian Chen
-
Publication number: 20140314773Abstract: The present disclosure provides for a hyperimmune preparation comprising human polyclonal antibodies or fragments thereof specific to a cyclic peptide having an amino acid sequence comprising SNK. The cyclic peptide may comprise an amino acid sequence GSNK (SEQ ID NO: 1), SNKG(SEQ ID NO: 2), GSNKG (SEQ ID N0:3), CSNKG (SEQ ID NO: 4), CGSNKGC (SEQ ID NO: 5), CGSNKGG (SEQ ID NO: 6), or CCGSNKGC (SEQ ID NO: 7). The antibodies in the hyperimmune preparation may have a titer ranging from about 200 to about 400 mean fluorescence intensity (MFI). In one embodiment, greater than about 80% of the antibodies in the hyperimmune preparation are IgG. The fragments of the antibodies are Fab, F(ab?)2, scFv, disulfide linked Fv, or mixtures thereof.Type: ApplicationFiled: November 12, 2012Publication date: October 23, 2014Inventors: Neil R. Cashman, Grant McClarty
-
Publication number: 20140315212Abstract: The present invention relates to a method for the purification, concentration and identification of glycosylphosphatidylinositol anchored proteins (GPI-APs) from a biological sample (cells, tissues and/or blood/serum) in a patient or subject, including a human patient or subject. A new method to separate GPI-anchored glycoproteins, a class of glycoproteins found in all animal cells and fluids including serum, from other glycoproteins and proteins for the purpose of identifying potential biomarkers for various diseases, including cancer, especially breast cancer, vaginal cancer, endometrial cancer, uterine cancer, cervical cancer, pancreatic cancer and prostate cancer. The method uses the alpha-toxin from Clostridium septicum to separate GPI-anchored glycoproteins for identification and optionally quantification. The GPI-APs so obtained may be used to raise antibodies for inclusion in an immunosorbent assay for the diagnosis or the monitoring of therapy of cancer in a patient.Type: ApplicationFiled: January 28, 2014Publication date: October 23, 2014Applicant: University of Georgia Research Foundation, Inc.Inventors: James Michael Pierce, Karen Lynn Abbott
-
Publication number: 20140317778Abstract: The invention further relates to vectors, host cells, seeds, and plants comprising such a nucleic acid molecule. One aspect of the invention is an isolated antibody or antigen binding fragment thereof that specifically binds to a polypeptide molecule of the present invention. One aspect of the invention is a plane or plant cell transfected by a vector of the present invention. One aspect of the invention relates to isolated nucleic acid molecules and fragments thereof encoding enzymes or proteins involved in disease resistance in jute.Type: ApplicationFiled: June 8, 2012Publication date: October 23, 2014Applicant: BANGLADESH JUTE RESEARCH INSTITUTEInventors: Maqsudul Alam, Haseena Khan, Mahboob Zaman, Mohammed K. Uddin, Mohammed S. Haque, Mohammed S. Islam, Muhammad S. Azam, Niaz Mahmood
-
Publication number: 20140314837Abstract: The present invention provides means for treating, alleviating and preventing amyloid-related pathology in young to middle-aged subjects with Down's syndrome (DS). In particular, the present invention provides antigenic peptide fragments derived from amyloid protein or amyloid-like protein for use in the preventive treatment of amyloid-related pathology in young to middle-aged subjects with Down's syndrome.Type: ApplicationFiled: September 21, 2012Publication date: October 23, 2014Inventors: Andrea Pfeifer, Andreas Muhs, Rime Madani, Pavel Vasilyevich Belichencko, William Charles Mobley
-
Publication number: 20140314830Abstract: The present invention relates to a new isolated polypeptide nominated microcin S, isolated nucleic acid molecules encoding the microcin S polypeptide and primers and probes hybridizing to the nucleic acid molecules. The invention also relates to plasmids and cells comprising the nucleic acid molecules, an antibody binding to the polypeptide, compositions as well as methods for producing and using the polypeptides. The present invention further relates to medical uses for treating or preventing microbial infections, functional gastrointestinal disorders or treating a tumor. The invention further relates to a method for preserving food and a method for coating dressing material.Type: ApplicationFiled: August 13, 2012Publication date: October 23, 2014Applicant: SYMBIOGRUPPE GMBH & CO. KGInventors: Florian Gunzer, Anke Zschuettig, Kurt Zimmermann